Effectiveness of BA.1-and BA.4/BA. 5-Containing Bivalent COVID-19 mRNA Vaccines Against Symptomatic SARS-CoV-2 Infection During the BA.5-Dominant Period in Japan

被引：11

作者：

Arashiro, Takeshi ^{[1
,2
,3
,4
]}

Arima, Yuzo ^{[1
]}

Kuramochi, Jin ^{[5
,6
]}

Muraoka, Hirokazu ^{[7
]}

Sato, Akihiro ^{[8
]}

Chubachi, Kumi ^{[9
]}

Yanai, Atsushi ^{[10
]}

Arioka, Hiroko ^{[10
]}

Uehara, Yuki ^{[11
,12
]}

Ihara, Genei ^{[13
]}

Kato, Yasuyuki ^{[14
]}

Yanagisawa, Naoki ^{[15
]}

Ueda, Akihiro ^{[16
]}

Kato, Hideaki ^{[17
]}

Oka, Hideaki ^{[18
]}

Nishida, Yusuke ^{[18
]}

Nidaira, Yuki ^{[5
]}

Asami, Takahiro ^{[19
]}

Jinta, Torahiko ^{[20
]}

Nakamura, Akira ^{[21
]}

Oba, Kunihiro ^{[22
]}

Taniyama, Daisuke ^{[23
]}

Yamamoto, Kei ^{[18
]}

Tanaka, Katsushi ^{[17
]}

Ueshima, Kankuro ^{[24
]}

Fuwa, Tetsuji ^{[24
]}

Stucky, Ashley ^{[1
]}

Suzuki, Tadaki ^{[2
]}

Smith, Chris ^{[3
]}

Hibberd, Martin ^{[3
]}

Ariyoshi, Koya ^{[4
]}

Suzuki, Motoi ^{[1
]}

机构：

[1] Natl Inst Infect Dis, Ctr Surveillance Immunizat & Epidemiol Res, Tokyo, Japan

[2] Natl Inst Infect Dis, Dept Pathol, Tokyo, Japan

[3] London Sch Hyg & Trop Med, Fac Infect & Trop Dis, London, England

[4] Nagasaki Univ, Sch Trop Med & Global Hlth, Nagasaki, Japan

[5] Kuramochi Clin Interpk, Tochigi, Japan

[6] Tokyo Med & Dent Univ, Dept Global Hlth Promot, Tokyo, Japan

[7] Clin TAMACHI, Tokyo, Japan

[8] KARADA Internal Med Clin, Tokyo, Japan

[9] Chubachi Internal Resp Med Clin, Tokyo, Japan

[10] St Lukes Int Hosp, Dept Gen Internal Med, Tokyo, Japan

[11] St Lukes Int Hosp, Dept Clin Lab, Tokyo, Japan

[12] Fujita Hlth Univ, Sch Med, Dept Infect Dis, Aichi, Japan

[13] Machida Ekimae Naika Clin, Tokyo, Japan

[14] Int Univ Hlth, Welf Narita Hosp, Dept Infect Dis, Chiba, Japan

[15] Yanagisawa Clin, Tokyo, Japan

[16] Japanese Red Cross Med Ctr, Dept Infect Dis, Tokyo, Japan

[17] Yokohama City Univ Med, Infect Prevent & Control Dept, Yokohama, Japan

[18] Saitama Med Ctr, Dept Gen Internal Med & Infect Dis, Saitama, Japan

[19] Sano Kosei Gen Hosp, Dept Internal Med, Tochigi, Japan

[20] St Lukes Int Hosp, Dept Pulm Med, Tokyo, Japan

[21] Asahi Gen Hosp, Dept Internal Med, Chiba, Japan

[22] Showa Gen Hosp, Dept Pediat, Tokyo, Japan

[23] Showa Gen Hosp, Dept Infect Dis, Tokyo, Japan

[24] NATURALI Co Ltd, Tokyo, Japan

来源：

OPEN FORUM INFECTIOUS DISEASES | 2023年 / 10卷 / 06期

关键词：

COVID-19; SARS-CoV-2; variants; test-negative design; vaccine effectiveness;

D O I：

10.1093/ofid/ofad240

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

In this multicenter, prospective, test-negative, case-control study in Japan, the effectiveness of both BA.1-containing and BA.4/BA.5-containing bivalent coronavirus disease 2019 mRNA vaccines against symptomatic infection during the BA.5-dominant period was high compared with no vaccination (65% and 76%) and moderate compared with monovalent vaccines administered over half a year earlier (46% combined). In this multi-center study in Japan, the effectiveness of both BA.1-containing and BA.4/BA.5-containing bivalent vaccines against symptomatic infection during the BA.5-dominant period was high compared to no vaccination (65%/76%) and moderate compared to monovalent vaccines >6 months before (46% combined).

引用

页数：6

共 50 条

[21] Omicron Variant-Specific Serological Imprinting Following BA.1 or BA.4/5 Bivalent Vaccination and Previous SARS-CoV-2 Infection: A Cohort Study
Baerends, Eva A. M.
Reekie, Joanne
Andreasen, Signe R.
Staerke, Nina B.
Raben, Dorthe
Nielsen, Henrik
Petersen, Kristine T.
Johansen, Isik S.
Lindvig, Susan O.
Madsen, Lone W.
Wiese, Lothar
Iversen, Mette B.
Benfield, Thomas
Iversen, Kasper K.
Larsen, Fredrikke D.
Andersen, Sidsel D.
Juhl, Anna K.
Dietz, Lisa L.
Hvidt, Astrid K.
Ostrowski, Sisse R.
Krause, Tyra G.
ostergaard, Lars
Sogaard, Ole S.
Lundgren, Jens
Tolstrup, Martin
CLINICAL INFECTIOUS DISEASES, 2023, 77 (11) : 1511 - 1520
[22] Effectiveness of Booster Doses of Monovalent mRNA COVID-19 Vaccine Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Children, Adolescents, and Adults During Omicron Subvariant BA.2/BA.2.12.1 and BA.4/BA.5 Predominant Periods
Ciesla, Allison Avrich
Wiegand, Ryan E.
Smith, Zachary R.
Britton, Amadea
Fleming-Dutra, Katherine E.
Miller, Joseph
Accorsi, Emma K.
Verani, Jennifer R.
Shang, Nong
Derado, Gordana
Pilishvili, Tamara
Link-Gelles, Ruth
OPEN FORUM INFECTIOUS DISEASES, 2023, 10 (05):
[23] A meta-analysis on the immunogenicity of prototype, monovalent-adapted and bivalent vaccines against SARS-CoV-2 wildtype, Omicron BA.1 and Omicron BA.4/5 in healthy adults
Ndzouboukou, Jo-Lewis Banga
Kamara, Abdul A.
Ullah, Nadeem
Lei, Qing
Fan, Xiong-lin
VIROLOGY, 2025, 606
[24] Association of SARS-CoV-2 BA.4/BA.5 Omicron lineages with immune escape and clinical outcome
Lewnard, Joseph A.
Hong, Vennis
Kim, Jeniffer S.
Shaw, Sally F.
Lewin, Bruno
Takhar, Harpreet
Tartof, Sara Y.
NATURE COMMUNICATIONS, 2023, 14 (01)
[25] Comparative Effectiveness of the Bivalent (Original/Omicron BA.4/BA.5) mRNA COVID-19 Vaccines mRNA-1273.222 and BNT162b2 Bivalent in Adults with Underlying Medical Conditions in the United States
Kopel, Hagit
Nguyen, Van Hung
Bogdanov, Alina
Winer, Isabelle
Boileau, Catherine
Ducruet, Thierry
Zeng, Ni
Winer-Jones, Jessamine P.
Esposito, Daina B.
Bausch-Jurken, Mary
Beck, Ekkehard
Bonafede, Machaon
Mansi, James A.
VACCINES, 2024, 12 (10)
[26] Immune responses in COVID-19 patients during breakthrough infection with SARS-CoV-2 variants Delta, Omicron-BA.1 and Omicron-BA.5
Bormann, Maren
Brochhagen, Leonie
Alt, Mira
Otte, Mona
Thuemmler, Laura
van de Sand, Lukas
Kraiselburd, Ivana
Thomas, Alexander
Gosch, Jule
Brass, Peer
Ciesek, Sandra
Widera, Marek
Dolff, Sebastian
Dittmer, Ulf
Witzke, Oliver
Meyer, Folker
Lindemann, Monika
Schoenfeld, Andreas
Rohn, Hana
Krawczyk, Adalbert
FRONTIERS IN IMMUNOLOGY, 2023, 14
[27] The viral fitness and intrinsic pathogenicity of dominant SARS-CoV-2 Omicron sublineages BA.1, BA.2, and BA.5
Shuai, Huiping
Chan, Jasper Fuk-Woo
Hu, Bingjie
Chai, Yue
Yoon, Chaemin
Liu, Huan
Liu, Yuanchen
Shi, Jialu
Zhu, Tianrenzheng
Hu, Jing-Chu
Hu, Ye-fan
Hou, Yuxin
Huang, Xiner
Yuen, Terrence Tsz-Tai
Wang, Yang
Zhang, Jinjin
Xia, Yao
Chen, Lin-Lei
Cai, Jian-Piao
Zhang, Anna Jinxia
Yuan, Shuofeng
Zhou, Jie
Zhang, Bao-Zhong
Huang, Jian-Dong
Yuen, Kwok-Yung
To, Kelvin Kai-Wang
Chu, Hin
EBIOMEDICINE, 2023, 95
[28] Results of contact tracing for SARS-CoV-2 Omicron sub-lineages (BA.4, BA.5, BA.2.75) and the household secondary attack risk
Yu, Mi
Lee, Sang-Eun
Lee, Hye Young
Kim, Hye-Jin
Song, Yeong-Jun
Jeong, Jian
Park, Ae Kyung
Kim, Il-Hwan
Kim, Eun-Jin
Park, Young-Joon
OSONG PUBLIC HEALTH AND RESEARCH PERSPECTIVES, 2023, 14 (03) : 173 - 179
[29] Humoral response superiority of the monovalent XBB.1.5 over the bivalent BA.1 and BA.5 mRNA COVID-19 vaccines
Lustig, Yaniv
Barda, Noam
Weiss-Ottolenghi, Yael
Indenbaum, Victoria
Margalit, Ili
Asraf, Keren
Doolman, Ram
Chalkias, Spyros
Das, Rituparna
Elfatarany, Gamal
Harats, Dror
Kreiss, Yitshak
Regev-Yochay, Gili
VACCINE, 2024, 42 (22)
[30] Effectiveness of primary series, first, and second booster vaccination of monovalent mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections and severe diseases during the SARS-CoV-2 omicron BA.5 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS)
Maeda, Haruka
Saito, Nobuo
Igarashi, Ataru
Ishida, Masayuki
Terada, Mayumi
Masuda, Shingo
Osawa, Ryosuke
Hosokawa, Naoto
Nakashima, Kei
Kamura, Hiroshi
Imura, Haruki
Inoue, Hiroki
Matsuzaka, Suguru
Sugimoto, Yukihiro
Kuwamitsu, Osamu
Motohashi, Iori
Morikawa, Toru
Oda, Rentaro
Hoshina, Yuiko
Matono, Takashi
Teshigahara, Osamu
Sando, Eiichiro
Asami, Sadaharu
Kudo, Satoshi
Akizuki, Noboru
Muto, Yoshikazu
Hayakawa, Tomoichiro
Kishaba, Tomoo
Ohara, Yasuji
Kubo, Yoshinao
Suzuki, Motoi
Morimoto, Konosuke
EXPERT REVIEW OF VACCINES, 2024, 23 (01) : 213 - 225

← 1 2 3 4 5 →